Lifeward sales slip 12% as ReWalk revenue falls during distributor switch
AlterG growth of 18% was not enough to offset weaker ReWalk exoskeleton sales at Lifeward, which reported a $5.1m quarterly loss and $4.5m of unrestricted cash.
Lifeward Ltd. posted revenue of $5.4m for the three months to September 2026, 12% below the same quarter a year earlier, in results released on 13 November. The decline came as the company shifted ReWalk exoskeleton sales away from a direct model and towards third-party distributors.
AlterG was the bright spot. Revenue from the business rose 18% year on year to $3.6m, making it roughly two-thirds of the group total. ReWalk contributed $1.7m, a decline on the prior year, according to the company's figures.
Profitability weakened. Gross margin was 27.4% and the net loss for the quarter was $5.1m. Unrestricted cash at the end of the period was $4.5m, a balance smaller than the loss booked over the quarter.
The information available does not say how fast the ReWalk transition is proceeding, what drove the margin, or what the company expects for coming quarters. It is therefore unclear how far the distribution change will affect results in future periods.
Why it matters
- Lifeward's revenue mix is tilting towards AlterG, the growing line, while ReWalk, the exoskeleton franchise, shrinks during a change in how it reaches customers.
- Moving ReWalk to distributors could alter who customers and payers deal with for powered exoskeletons, a point for market-access teams tracking the category.
- Distributors taking on ReWalk may need to clarify how duties such as complaint handling and post-market surveillance are divided with the manufacturer.
- A $5.1m quarterly loss, a 27.4% gross margin and $4.5m of unrestricted cash are figures counterparties may weigh in supplier and partner due diligence.
Company's press release (SEC filing): Lifeward Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
